Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 2/20 | 0.50 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.44 |
| ▸ | CKS1B | P61024 | 1/20 | 0.44 |
| ▸ | SKP1 | P63208 | 1/20 | 0.44 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.44 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 4/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16811854 | 0.92 | SMO (0.51) | SMOAKT1CKS1BSKP1SKP2 | |
| SCHEMBL16811820 | 0.91 | SMO (0.50) | SMOAKT1CKS1BSKP1SKP2 | |
| SCHEMBL16811816 | 0.90 | SMO (0.54) | SMOPDCD1CD274MCHR1SLC6A12 | |
| SCHEMBL16811809 | 0.89 | SMO (0.52) | SMOAKT1PDCD1CD274CKS1B | |
| SCHEMBL16811825 | 0.89 | SMO (0.59) | SMOPDCD1CD274MCHR1SLC6A12 | |
| SCHEMBL16811834 | 0.89 | SMO (0.61) | SMOAKT1PDCD1CD274CKS1B | |
| SCHEMBL16811788 | 0.88 | SMO (0.51) | SMOAKT1PDCD1CD274CKS1B | |
| SCHEMBL18286470 | 0.88 | SMO (0.49) | SMOAKT1PDCD1CD274CKS1B | |
| SCHEMBL16811862 | 0.86 | SMO (0.55) | SMOAKT1CKS1BSKP1SKP2 | |
| SCHEMBL18286599 | 0.85 | CHRM4 (0.46) | SMOAKT1PDCD1CD274CKS1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9512106-B2 | Smoothened modulators and methods of use thereof | DUKE UNIVERSITY (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512106-B2 | Smoothened modulators and methods of use thereof | DUKE UNIVERSITY (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150166509-A1 | SMOOTHENED MODULATORS AND METHODS OF USE THEREOF | UNIV DUKE (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150166509-A1 | SMOOTHENED MODULATORS AND METHODS OF USE THEREOF | UNIV DUKE (US) | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166509-A1 | SMOOTHENED MODULATORS AND METHODS OF USE THEREOF | SMO, SHH, GLI1 | SMO 1/4885AKT1 137/4885PDCD1 4160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.